Central Retinal Vein Occlusion

Inclusion Criteria

-  Center-involved macular edema secondary to CRVO for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit).
 -  Adult subjects diagnosed with macular edema secondary to CRVO who are scheduled to be treated with IVT aflibercept as per investigator’s routine treatment practice with the intent to use a T&E regimen after initial dosing.
 -  Treatment-naïve subjects for macular edema secondary to CRVO.
 -  Men and women ≥ 18 years of age.
 -  Documented BCVA of ETDRS letter score of 73 to 24 letters (Snellen equivalent of 20/40 to 20/320) in the study eye.

Exclusion Criteria

-  Previous PRP or macular laser photocoagulation in the study eye.
 -  Any prior or concomitant ocular treatment (e.g. anti-VEGF therapy, corticosteroids) in the study eye for macular edema secondary to RVO, except dietary supplements or vitamins prior to inclusion in the study. Intraocular anti-VEGF treatment is permitted for the treatment of diseases of fellow eye except for those that are specifically excluded.
 -  Prior systemic anti-VEGF or corticosteroid therapy, investigational or approved, within the last 3 months before the first dose in the study.
 -  Previous use of intraocular corticosteroids in the study eye at any time or use of periocular corticosteroids in the study eye within 12 months prior to Day 1.
 -  Any active intraocular, extraocular, and periocular inflammation or infection in either
eye within 4 weeks of screening.
 -  Any history of allergy to povidone iodine.
 -  Known serious allergy to the fluorescein sodium for injection in angiography.
 -  Presence of any contraindications indicated in the EU commission/locally approved label for IVT aflibercept: hypersensitivity to the active substance IVT aflibercept or to any of the excipients; active or suspected ocular or periocular infection; active severe intraocular inflammation.